Dimensional Fund Advisors LP Has $1.40 Million Holdings in 2seventy bio, Inc. (NASDAQ:TSVT)

Dimensional Fund Advisors LP raised its holdings in 2seventy bio, Inc. (NASDAQ:TSVT) by 68.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 475,118 shares of the company’s stock after buying an additional 193,305 shares during the period. Dimensional Fund Advisors LP owned about 0.92% of 2seventy bio worth $1,397,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of TSVT. American Century Companies Inc. increased its stake in shares of 2seventy bio by 6.6% during the fourth quarter. American Century Companies Inc. now owns 93,552 shares of the company’s stock worth $275,000 after purchasing an additional 5,785 shares during the period. Intech Investment Management LLC boosted its holdings in shares of 2seventy bio by 41.1% in the 4th quarter. Intech Investment Management LLC now owns 20,688 shares of the company’s stock valued at $61,000 after purchasing an additional 6,030 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of 2seventy bio by 23.2% in the 4th quarter. Wells Fargo & Company MN now owns 32,532 shares of the company’s stock valued at $96,000 after purchasing an additional 6,133 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of 2seventy bio by 9.5% during the 4th quarter. Rhumbline Advisers now owns 84,670 shares of the company’s stock valued at $249,000 after acquiring an additional 7,379 shares in the last quarter. Finally, Barclays PLC boosted its holdings in shares of 2seventy bio by 12.7% during the 4th quarter. Barclays PLC now owns 90,795 shares of the company’s stock valued at $267,000 after acquiring an additional 10,201 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. Leerink Partnrs downgraded 2seventy bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of 2seventy bio in a research report on Saturday, May 10th. Morgan Stanley decreased their target price on 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Friday, March 14th. Finally, Leerink Partners reissued a “market perform” rating and set a $5.00 price objective (down from $9.00) on shares of 2seventy bio in a report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $4.25.

2seventy bio Price Performance

Shares of NASDAQ TSVT opened at $5.00 on Friday. 2seventy bio, Inc. has a twelve month low of $2.29 and a twelve month high of $5.30. The stock’s 50 day moving average price is $4.97 and its 200-day moving average price is $3.77. The company has a market capitalization of $266.15 million, a PE ratio of -2.69 and a beta of 1.04.

2seventy bio (NASDAQ:TSVT) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.11. 2seventy bio had a negative return on equity of 53.65% and a negative net margin of 207.25%. The business had revenue of $22.94 million for the quarter, compared to the consensus estimate of $13.96 million. As a group, research analysts expect that 2seventy bio, Inc. will post -1.46 EPS for the current fiscal year.

Insider Activity at 2seventy bio

In other 2seventy bio news, major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $4.93, for a total transaction of $25,350,607.23. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO William D. Baird III sold 5,092 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $4.95, for a total transaction of $25,205.40. Following the completion of the transaction, the chief executive officer now directly owns 1,121,034 shares in the company, valued at approximately $5,549,118.30. The trade was a 0.45% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,152,093 shares of company stock worth $25,400,018. Insiders own 7.20% of the company’s stock.

2seventy bio Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.